1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: During the three months ended June 30, 2026, Michael McBreen , the Company’s Executive Vice President and Chief Commercial Officer , adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act on June 11, 2026 to sell up to 27,040 shares of our common stock between September 10, 2026 and September 13, 2027 , the date this plan expires.
−Removed: The sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of (i) the date all the shares under the plan are sold and (ii) September 13, 2027.
−Removed: Other than as disclosed above, none of the Company’s directors or officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K) during the three months ended June 30, 2026.
+Added: During the three months ended September 30, 2026, none of the Company’s directors or officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”
3.1(a) Amended and Restated Certificate of Incorporation of the Company dated February 16, 1993 (Incorporated by reference to Exhibit 3.1(a) to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2005)
4 unchanged sentences
3.2 Third Amended and Restated Bylaws of Integra LifeSciences Holdings Corporation, effective as of February 21, 2023 (Incorporated by reference to Exhibit 3.3 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed on February 22, 2023)
−Removed: 10.1 Eighth Amended and Restated Credit Agreement, dated as of April 10, 2026, among Integra LifeSciences Holdings Corporation, the lenders party thereto, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, Citibank N.A., JPMorgan Chase Bank, N.A., Morgan Stanley MUFG Loan Partners, LLC, PNC Bank, N.A., Truist Securities, Inc.
−Removed: and Wells Fargo Bank, N.A., as Co-Syndication Agents, and The Bank of Nova Scotia, BMO Harris Bank N.A., BNP Paribas, Capital One, National Association, Citizens Bank, N.A., DNB Bank ASA, New York Branch, Santander Bank, N.A.
−Removed: and TD Bank, N.A., as Co-Documentation (Incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 3 1 , 2026, filed on May 5, 2026)
−Removed: 10.2 Amendment No.
−Removed: 1 to Purchase and Sale Agreement, dated as of April 10, 2026, by and among Integra Receivables LLC, Integra LifeSciences Sales LLC, Integra LifeSciences Corporation, and acknowledged and agreed to by PNC Bank, N.A.
−Removed: (Incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended M arch 3 1 , 2026, filed on May 5, 2026)
−Removed: 10.3* Amendment No.
−Removed: 3 to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 8, 2026)
−Removed: 10.4* Integra LifeSciences Holdings Corporation Directors Deferred Compensation Plan (Incorporated by reference to Exhibit 10.13 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed on February 26, 2026)
−Removed: 10.5*+ Employment Agreement, dated May 1, 2026, by and between Integra LifeSciences Holdings Corporation, Integra LifeSciences Corporation and Stuart Essig
−Removed: 10.6*+ Form of Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan Restricted Stock Unit Award Agreement (May 2026)
−Removed: 10.7*+ Form of Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan Non-Qualified Stock Option Award Agreement (May 2026)
−Removed: 10.8*+ Separation and General Release Agreement, dated May 1, 2026, by and among Mojdeh Poul, Integra LifeSciences Holdings Corporation and Integra LifeSciences Corporation
+Added: 4.1 Indenture, dated as of October 19, 2026, by and between Integra LifeSciences Holdings Corporation, Truist Bank, as trustee and notes collateral agent, and the guarantor parties thereto (Incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed on October 19, 2026)
+Added: 10.1 Amended and Restated Credit Agreement, dated October 19, 2026, among Integra LifeSciences Holdings Corporation, the lenders party thereto, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, [JPMorgan Chase Bank, N.A., Citigroup Global Markets Inc., Citizens Bank, N.A., DNB Carnegie Inc., PNC Capital Markets LLC, Truist Securities, Inc., Capital One, National Association, Goldman Sachs Bank USA, Wells Fargo Securities, LLC, BMO Capital Markets Corp., Santander Bank, N.A., The Huntington National Bank, Morgan Stanley Senior Funding, Inc.
+Added: and MUFG Bank, Ltd.], as Co-Syndication Agents, and The Bank of Nova Scotia and Pinnacle Bank, a Tennessee chartered bank, d/b/a Synovus Bank, as Co-Documentation Agents (Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on October 19, 2026)
+Added: 10.2 Ratification Agreement, dated as of October 19, 2026, between Integra LifeSciences Holdings Corporation, the Subsidiary Guarantors of Integra LifeSciences Holdings Corporation and Bank of America, N.A., as Administrative Agent (Incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed on October 19, 2026)
+Added: 10.3*+ Form of Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan Restricted Stock Unit Award Agreement (2026)
+Added: 10.4*+ Form of Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan Non-Qualified Stock Option Award Agreement (2026)
31.1+ Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
11 unchanged sentences
+ Indicates this document is filed as an exhibit herewith.
−Removed: # The financial information of Integra LifeSciences Holdings Corporation Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 filed on July 29, 2026 formatted in XBRL (Extensible Business Reporting Language):
+Added: # The financial information of Integra LifeSciences Holdings Corporation Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 filed on October 23, 2026 formatted in XBRL (Extensible Business Reporting Language):
(i) the Condensed Consolidated Statements of Operations and Comprehensive Income, (ii) the Condensed Consolidated Balance Sheets, (iii) Parenthetical Data to the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements, is furnished electronically herewith.
1 unchanged sentence
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
−Removed: July 29, 2026 /s/ Stuart M.
+Added: October 23, 2026 /s/ Stuart M.
Chairman, President and Chief Executive Officer
(Principal Executive Officer)
−Removed: July 29, 2026 /s/ Lea Knight
+Added: October 23, 2026 /s/ Lea Knight
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
−Removed: July 29, 2026 /s/ Jeffrey A.
+Added: October 23, 2026 /s/ Jeffrey A.
Senior Vice President, Finance
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.